Nexalis Therapeutics Limited (ASX:NX1)
Australia flag Australia · Delayed Price · Currency is AUD
0.0150
0.00 (0.00%)
Sep 25, 2026, 10:49 AM AEST

Nexalis Therapeutics Revenue

Nexalis Therapeutics had revenue of 630.10K AUD in the half year ending June 30, 2026, with 419.05% growth. This brings the company's revenue in the last twelve months to 1.07M, up 28.04% year-over-year. In the year 2025, Nexalis Therapeutics had annual revenue of 986.43K with 145.50% growth. That makes Nexalis Therapeutics the 44,016th largest company in the world by revenue and 999th in Australia.

Revenue (ttm)
1.07M
Revenue Growth
+28.04%
P/S Ratio
3.56
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.80M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025986.43K584.62K145.50%
Dec 31, 2024401.81K-802.24K-66.63%
Dec 31, 20231.20M1.18M4,755.02%
Dec 31, 202224.80K-156.94K-86.35%
Dec 31, 2021181.74K159.61K721.35%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Immuron7.71M
Acrux6.58M
Tissue Repair2.99M
Vectus Biosystems2.77M
Cynata Therapeutics1.71M
Bio-Gene Technology1.08M
Biotron525.87K
AdAlta404.25K
Revenue Rankings